Andrew Niles1, Nathan Evans1, Michael A. Scurria2, Tim Ugo2, Gediminas Vidugiris1, and Thomas Kirkland2
1Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711
2Promega Biosciences LLC, 277 Granada Dr., San Luis Obispo, CA 93401
Histone deacetylases (HDACs) play key roles in gene regulation by modifying the acetylation status of core histones as well as a number of non-histone regulatory proteins. Therefore, modulation of HDAC activities represents an emerging paradigm in treating diseases as diverse as cancer, asthma and neurodegeneration. Unfortunately, the biological relationships between specific HDACs and phenotype or disease state are poorly characterized and more effective tools are sought for defining these relationships. Here we describe the assay's utility in relevant cell and enzyme models with a variety of HDAC inhibitory (HDACi) compounds of varying structure.